Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 January 2016 00:00
- Written by Liz Highleyman
An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of non-cirrhotic hepatitis C patients with HCV genotypes 1, 2, or 3, according to late-breaking research presented at the AASLD Liver Meeting in November.
AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 December 2015 00:00
- Written by Liz Highleyman
Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C coinfection, was well-tolerated, and did not appear to interact with antiretrovirals, according to final results from the C-EDGE Co-infection study presented at the 2015 AASLD Liver Meeting last month in San Francisco. These results confirm that HIV/HCV coinfected people respond as well to interferon-free therapy as those with HCV alone.
AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 18 November 2015 00:00
- Written by Liz Highleyman
A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced, cirrhotic, genotype 1 hepatitis C patients without the need for ribavirin, according to study findings presented at the AASLD Liver Meeting this week in San Francisco.
AASLD 2015: Intensification with Sofosbuvir Permits Cure after Previous HCV Treatment Failure
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 19 November 2015 00:00
- Written by Keith Alcorn
Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir (Sovaldi), a pair of studies presented at the AASLD Liver Meeting this week in San Francisco have shown.
AASLD 2015: New AbbVie Hepatitis C Combination Cures Up to 97% with Genotype 3
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 18 November 2015 00:00
- Written by Keith Alcorn
A combination of 2 experimental direct-acting antivirals developed by AbbVie cured 83%-97% of people with genotype 3 hepatitis C after a 12-week course of treatment, Paul Kwo from Indiana University School of Medicine reported at the 2015 AASLD Liver Meeting this week in San Francisco.
More Articles...
- AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C
- AASLD 2015: New AbbVie Pangenotypic Regimen Cures 97%-100% of Hepatitis C Patients in Early Study
- AASLD 2015: Sofosbuvir/ Velpatasvir Shows High Cure Rates for All HCV Genotypes in Phase 3
- AASLD 2015: Sofosbuvir/ Velpatasvir + GS-9857 for 8 Weeks Cures Most Genotype 1 or 3 Hepatitis C Patients
Web Design and Development by